Brief: Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results For Palazestrant
22/10/2023 07:57
Oct 22 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES POSITIVE PHASE 2 MONOTHERAPY
CLINICAL
STUDY RESULTS FOR PALAZESTRANT
* RESULTS SUPPORT CONTINUED DEVELOPMENT OF PALAZESTRANT IN
OPERA-01 MONOTHERAPY PHASE 3 PIVOTAL TRIAL
* ACROSS ALL 86 HEAVILY PRETREATED PATIENTS, MEDIAN PFS WAS
4.6
MONTHS WITH A CBR OF 40%
Source text for Eikon: ID:nGNX4tY2Wn
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs